secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2024-09-20T23:59:59+00:00
Accession:  0000950170-24-108465
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Pharmaceuticals enters $75M at-the-market equity facility with Guggenheim Securities
--------------------------------------------------------------------------------

- ATM sales agreement with Guggenheim Securities for up to $75M in common stock sales.
- Shares sold directly on Nasdaq under Rule 415; 3.0% gross proceeds commission to Guggenheim.
- Company may terminate agreement with ten trading days' notice; no obligation to sell.
- Shelf registration statement on Form S-3 filed concurrently; subject to SEC effectiveness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024108465/0000950170-24-108465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024108465/eldn-20240920.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-108465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer